Chinese biotechnology firm Ascletis Pharma becomes the first biotech company to apply for an initial public offering (IPO) in Hong Kong after the exchange implemented new, more relaxed listing rules that allow biotech firms to list even if they still have not made profit or revenue.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
